Illumina (ILMN) Stock News

Illumina (NASDAQ: ILMN) announced an expansion of its clinical oncology portfolio with two key developments. First, their TruSight™ (TSO) Comprehensive test, the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims, has gained broad payer reimbursement including Medicare and most commercial health plans. UofL Health became the first customer to implement the test. The test has also received regulatory approval in Japan.

Second, Illumina partnered with Pillar Biosciences to offer Pillar oncoReveal CDx, an IVD kit for detecting genetic variations in 22 genes for solid tumor patients. The test recently received nationwide Medicare coverage, making it accessible to over 66 million Medicare beneficiaries in the US.

Illumina (NASDAQ: ILMN) has announced its participation in the upcoming 41st Annual Bernstein Strategic Decisions Conference. The company's executives will engage in a fireside chat on May 28, 2025, at 11:30 AM Pacific Time (2:30 PM Eastern Time). Investors and interested parties can access the webcast through the Investor Info section on investor.illumina.com. A replay of the presentation will be available on the company's website for a minimum of 30 days following the event.

Illumina (NASDAQ: ILMN) has launched DRAGEN v4.4, an enhanced secondary analysis software solution featuring significant improvements in accuracy and functionality. Key highlights include a 30% improvement in structural variant calling accuracy and a 20% boost in SNV and indel calling accuracy. The update introduces preconfigured oncology applications for clinical research, enhanced multiomics pipelines, and AWS F2 support for faster processing. The University Hospital of Tübingen has selected DRAGEN for a pioneering study to evaluate clinical utility in whole-genome germline testing. The software's new features include push-button analysis for oncology workflows, support for new multiomics assays, and improved cloud analysis capabilities. This release builds on DRAGEN's established leadership in variant calling accuracy, as validated in a peer-reviewed Nature Biotechnology study from October 2024.

Illumina (ILMN) reported Q1 2025 financial results with core revenue of $1.04 billion, down 1% year-over-year. The company posted GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4%. Q1 GAAP diluted EPS was $0.82, while non-GAAP diluted EPS reached $0.97. Cash flow from operations was $240 million with free cash flow of $208 million. The company revised its FY2025 guidance downward, now expecting core revenue to decline 1-3% on a constant currency basis. Revenue outside Greater China is projected to grow 0-2%, while Greater China revenue is expected at $165-185 million. The company faces $85 million in tariff-related costs, impacting operating margin by 125 bps and EPS by $0.25. Non-GAAP operating margin guidance was lowered to 21.5-22.0% from 23%, with EPS guidance reduced to $4.20-4.30 from $4.50.

Illumina and Ovation.io are launching a groundbreaking dataset featuring integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies. The collaboration aims to advance drug discovery and development in the pharmaceutical industry. Key highlights include:

The dataset will be the largest commercially available clinical multiomic dataset for GLP-1 therapies, incorporating whole-genome sequencing and protein expression profiling of 5,000 samples using Illumina's IPP assay that detects 9,500 human proteins per sample.

This initiative addresses significant market needs, as 1 in 8 adults in the US use GLP-1 receptor agonists, but approximately 40% of Type 2 diabetes patients don't respond effectively to these treatments. The dataset will help identify new indications, biomarkers, and drug targets, particularly for non-responsive patients.

Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.

The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.

The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.

Illumina (NASDAQ:ILMN) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

The earnings discussion will be led by CEO Jacob Thaysen, PhD, and CFO Ankur Dhingra, who will review the company's financial and operating results with analysts, investors, and other interested parties. Participants are advised to join the webcast at least ten minutes before the scheduled start time through Illumina's Investor Info section. A replay will be available on the company's website for a minimum of 30 days following the event.

Illumina (NASDAQ: ILMN) announced significant changes to its Board of Directors. Dr. Scott Gottlieb, who has served on the Board since 2020, has been elected as non-executive Chair. Additionally, Keith Meister, founder and Chief Investment Officer of Corvex Management, will join the Board on March 28, 2025.

Stephen MacMillan, who joined the Board in June 2023, will retire ahead of the upcoming annual shareholder meeting. Dr. Gottlieb expressed commitment to advancing the company's mission and driving profitable growth, while Meister voiced confidence in Illumina's strategy to expand its role in genomics and deliver shareholder value.

Illumina (NASDAQ: ILMN) and Nashville Biosciences (NashBio) announced the completion of sequencing 250,000 whole genomes for the Alliance for Genomic Discovery (AGD) initiative. The project, which began in January 2023, has created one of the largest clinical genomic datasets, completing ahead of the projected 2025 timeline.

The dataset, processed using Illumina's sequencing workflow and DRAGEN analysis pipeline, combines DNA samples from VUMC's BioVU® biobank with de-identified clinical data. Eight biopharma members access this data through Illumina Connected Analytics platform, already yielding novel target discoveries in autoimmune, liver fibrotic, and metabolic diseases.

According to a 2024 Nature study, drugs developed with genetic evidence are 2.6 times more likely to succeed. The next phase of AGD will expand into multiomics, exploring proteomics and other modalities to enhance understanding of disease mechanisms and drug target discovery.